"Youth Aware of Mental Health" in Galicia
Launched by FUNDACIN BIOMEDICA GALICIA SUR · Feb 1, 2024
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study in Galicia, Spain tests whether a school-based program called Youth Aware of Mental Health (YAM) can help prevent serious suicidal thoughts and suicide attempts among teenagers. It is a large, randomized trial in many secondary schools, where each school is assigned to either receive the YAM program or to continue with usual teaching (no extra program) during the study. The intervention group will take part in five one-hour, interactive sessions led by trained instructors; the control group will not receive YAM during the study but will be offered it after the study ends.
Eligible participants are 13 to 16-year-old students in 3rd-year secondary education at participating centers. Parents must give permission, and students aged 12 or older give assent. All students will complete surveys at the start and 12 months later to measure suicidal thoughts and behaviors, mood/depression, willingness to seek help, bullying, and related factors. The main goals are to see if YAM reduces severe suicidal ideation and prevents new suicide attempts compared with schools not receiving the program. Results are not yet available, as the trial is ongoing.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being a 3rd-year secondary education student at one of the participating school centers
- • To be between 13 and 16 years old
- Exclusion Criteria:
- • Not meeting the inclusion criteria
- • Note: The YAM is a universal prevention program, therefore, there are no exclusion criteria. Cases with a history of previous suicide attempts (evaluated by the Paykel Scale) in the initial survey will be excluded from the analysis. However, these students will receive the same intervention as the rest of the students. The YAM is not a treatment program and does not aim to demonstrate its efficacy in cases already diagnosed with mental disorders, but it does not exclude individuals with these problems from any potential benefits that participation in the program may have.
About Fundacin Biomedica Galicia Sur
Fundación Biomédica Galicia Sur is a leading clinical research organization dedicated to advancing medical science through innovative research and development. Based in Galicia, Spain, the foundation collaborates with healthcare institutions, academic researchers, and industry partners to facilitate high-quality clinical trials that focus on a range of therapeutic areas. With a commitment to ethical standards and patient-centric approaches, Fundación Biomédica Galicia Sur aims to translate scientific discoveries into effective treatments, ultimately enhancing healthcare outcomes and contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ferrol, A Coruñaa, Spain
Ares, A Coruña, Spain
Betanzos, A Coruña, Spain
Betanzos, A Coruña, Spain
Cambre, A Coruña, Spain
Carballo, A Coruña, Spain
Carballo, A Coruña, Spain
Culleredo, A Coruña, Spain
Ferrol, A Coruña, Spain
Ferrol, A Coruña, Spain
Ferrol, A Coruña, Spain
Noia, A Coruña, Spain
Ordes, A Coruña, Spain
Ordes, A Coruña, Spain
Padrón, A Coruña, Spain
Pontedeume, A Coruña, Spain
Sada, A Coruña, Spain
Santiago De Compostela, A Coruña, Spain
Santiago, A Coruña, Spain
Santiago, A Coruña, Spain
Vedra, A Coruña, Spain
Coristanco, Coruña, Spain
Ferrol, Coruña, Spain
Santiago De Compostela, Coruña, Spain
Burela De Cabo, Lugo, Spain
Monterroso, Lugo, Spain
Sarria, Lugo, Spain
Sarria, Lugo, Spain
Sarria, Lugo, Spain
Allariz, Ourense, Spain
Maceda, Ourense, Spain
O Carballiño, Ourense, Spain
O Carballiño, Ourense, Spain
Xinzo De Limia, Ourense, Spain
A Guarda, Pontevedra, Spain
Baiona, Pontevedra, Spain
Cangas, Pontevedra, Spain
Gondomar, Pontevedra, Spain
Marín, Pontevedra, Spain
Marín, Pontevedra, Spain
Moaña, Pontevedra, Spain
Mondariz, Pontevedra, Spain
Poio, Pontevedra, Spain
Redondela, Pontevedra, Spain
Salceda De Caselas, Pontevedra, Spain
Salvatierra De Miño, Pontevedra, Spain
Sanxenxo, Pontevedra, Spain
Soutomaior, Pontevedra, Spain
Tomiño, Pontevedra, Spain
Vigo, Pontevedra, Spain
Vigo, Pontevedra, Spain
Vigo, Pontevedra, Spain
Vigo, Pontevedra, Spain
Vigo, Pontevedra, Spain
Vigo, Pontevedra, Spain
A Coruña, Spain
A Coruña, Spain
Coruña, Spain
Lugo, Spain
Lugo, Spain
Lugo, Spain
Lugo, Spain
Ourense, Spain
Ourense, Spain
Ourense, Spain
Ourense, Spain
Pontevedra, Spain
Santiago De Compostela, Spain
Vigo, Pontevedra, Spain
Ferrol, Spain
Ares, Spain
Betanzos, Spain
Betanzos, Spain
Cambre, Spain
Carballo, Spain
Carballo, Spain
Culleredo, Spain
Ferrol, Spain
Ferrol, Spain
Ferrol, Spain
Noia, Spain
Ordes, Spain
Ordes, Spain
Padrón, Spain
Pontedeume, Spain
Sada, Spain
Santiago De Compostela, Spain
Santiago, Spain
Santiago, Spain
Vedra, Spain
Coristanco, Spain
Ferrol, Spain
Santiago De Compostela, Spain
Patients applied
Trial Officials
Alejandro García Caballero
Principal Investigator
Servizo Galego de Saude
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported